virulizin + 5-fluorouracil

Virulizin + 5-fluorouracil is a **combination regimen consisting of Virulizin, an immunotherapeutic biological response modifier, and 5-fluorouracil (5-FU), a cytotoxic antimetabolite chemotherapy**. This combination has been studied primarily in the treatment of advanced solid tumors, especially pancreatic cancer. **Virulizin acts by stimulating immune system cells (macrophages and natural killer cells) to produce cytokines such as IL-12, IL-17E, and TNF-alpha, resulting in enhanced innate immune-mediated antitumor effects**. **5-Fluorouracil interferes with both DNA and RNA synthesis in cancer cells, inhibiting their proliferation and inducing cell death**. The immunomodulatory and cytotoxic effects of the two agents provide mechanistic complementarity, with Virulizin enhancing host immune response and 5-FU directly targeting rapidly dividing tumor cells[1][2][3][4][5][6][7][8][9].

Other names

5-FU